Management of Cardiomegaly with Propranolol and Captopril

Diagnosis and Treatment Approach

The American College of Cardiology recommends obtaining an echocardiogram to assess left ventricular ejection fraction (LVEF) in patients with cardiomegaly and dyspnea, to determine the type of cardiomyopathy and guide treatment 1.
In patients with hypertrophic cardiomyopathy (HCM), beta-blockers like propranolol are the Class I recommendation for treating symptomatic HCM with dyspnea, and should be titrated to achieve a resting heart rate below 60-65 bpm 2, 4, 3, 1.
The American College of Cardiology guidelines state that ACE inhibitors like captopril are potentially harmful in HCM patients with resting or provocable LVOT obstruction (Class IIb/III evidence) 2, 5, 6, 7, 1.

The American College of Cardiology recommends discontinuing captopril immediately if LVOT obstruction is present in patients with HCM 3, 8.
In patients with HCM, propranolol should be started at low doses and titrated to heart rate <60-65 bpm (up to maximum tolerated doses) 2, 4, 3.
The American College of Cardiology recommends monitoring patients with HCM closely for bradycardia or conduction abnormalities when treated with propranolol 2, 4.

In patients with systolic heart failure (LVEF <50%), captopril is the preferred agent, and has demonstrated significant improvement in symptoms, exercise tolerance, and ejection fraction 1, 7.
The American College of Cardiology recommends using beta-blockers with caution in patients with systolic heart failure, and only adding propranolol if the patient is euvolemic, well-compensated, and under close monitoring 1.

When using the combination of captopril and propranolol, monitor blood pressure, heart rate, renal function, signs of worsening heart failure, and hypoglycemia risk 2, 3.
The American College of Cardiology recommends avoiding the use of captopril in HCM with LVOT obstruction, as it can worsen symptoms and gradients 2, 6, 3.